Authors
Latest:
Use of the PRiSM Diagnostic Instrument in Clinical PracticeAre you ready to put the Psychopathology Refracted into 7 Modalities (PRiSM) Scale into practice? Learn more here.
Latest:
Is Video Game Addiction a Disorder?Is gaming dangerous? A study found 10% of video game players exhibited pathological behavior.
Latest:
Supporting the Mental Health of AAPI YouthIn honor of Asian American/Pacific Islander Heritage Month, we had a discussion on how best to support AAPI youth and their families.
Latest:
Rejecting the Accusation of a Violated STAR*D ProtocolThe original STAR*D authors refute claims of a violated protocol.
Latest:
How Would You Tackle Mental Health Disparities?Targeted and collaborative efforts are needed at individual and systemic levels to address underlying causes of mental health disparities.
Latest:
The Effects of Multidose Ketamine Treatment on Cognitive Performance Over Time in Patients With TRDExperts present the results of a retrospective analysis of patients who received IV ketamine for TRD over a timeframe of up to 2 years.
Latest:
Serotonin Reuptake Inhibitor and Bleeding Risk, Part 2: Gastrointestinal (GI) Bleeding, Malignancy, Pregnancy, and Surgical ConsiderationsIn this CME article, review literature on SRI-related bleeding complications in patients with GI bleeding, malignancy, perioperative settings, pregnancy, and hormonal therapy.
Latest:
Promising Strategies for Treatment-Resistant DepressionIn this CME, review novel, currently available, and promising pharmacological treatment options for treatment-resistant depression.
Latest:
Building Brain Resilience: A Multi-Level Systems ApproachBeyond the COVID-19-driven shock, we must develop a resilient future in an increasingly uncertain world.
Latest:
Ibogaine Found to Reduce Mood Disorder and PTSD Symptoms, Consumption of Alcohol in Patients With Alcohol Use DisorderHow can Ibogaine help patients with Alcohol Use Disorder, specifically in veterans?
Latest:
End-of-Life Care for Patients With Psychiatric DisordersIn this CME article, learn how best to provide end-of-life care to patients with psychiatric disorders.
Latest:
A Brainier Approach to ESG InvestingDevoting funds to better benefit brain health could improve society as a whole.
Latest:
Psychiatry and the “Worst Movie Ever Made”For psychiatrists, can a poorly made film contain themes worthy of analysis?
Latest:
Telepsychiatry: Diverse Needs Require Diverse OptionsCOVID-19 has prompted an unprecedented shift toward virtual psychiatric health care—but how do patients and providers really feel about it?
Latest:
The Waiting Game: Treating Patients With Intellectual Disabilities in the Emergency DepartmentEmergency departments face unique challenges in providing psychiatric care for individuals with intellectual and developmental disabilities, impacting wait times and overall experience.
Latest:
Attention to Attention is What You Need: Artificial Intelligence and MedicineHere's how medical practitioners and researchers can influence AI reasoning and influence in the future of AI development and deployment.
Latest:
ADHD: Overlooked Cause of Persistent Anxiety and Depression in AdultsIt’s time to address adult ADHD.
Latest:
8 Neuropsychiatric Symptoms and Treatments of Huntington DiseaseIn approximately half of patients with Huntington disease, symptoms of depression, irritability/aggression, executive dysfunction, psychosis, cognitive decline, and dementia present long before progressive motor symptoms.
Latest:
Bringing the Hospital Home: Meeting Teens in Crisis Where They AreLearn more about a feasible, scalable, effective model of care that is a step away from the forced dichotomy of inpatient and outpatient care.
Latest:
Facing Fears: Patients With Past Trauma Can Still Enjoy HalloweenJust because a patient has anxiety or past trauma does not mean they cannot enjoy this spooky holiday…
Latest:
Taking Up SpaceA nurse practitioner discusses author James Baldwin and the importance of moving from fear toward self-advocacy and self-love.
Latest:
MM120 Shows Rapid and Lasting Anxiety Reduction in Phase 3 Generalized Anxiety Disorder TrialsEarly phase 3 results show that a single dose of MM120 can rapidly reduce anxiety symptoms in GAD patients, with effects lasting up to 12 weeks.
Latest:
Insights From the 2022 AAPL Annual MeetingThe American Academy of Psychiatry and the Law hosted its first in-person meeting in October 2022. Check out these highlights.
Latest:
Post-Acute Sequelae of COVID-19 Infection Presenting With Neuropsychiatric Symptoms: Diagnosis and ManagementIn this CME article, learn more about the common neuropsychiatric sequelae of post-acute sequelae of COVID-19, the underlying neurobiological mechanisms, and evidence-based treatments and interventions.
Latest:
Revolutionizing the Role of Science in Making Health DecisionsMisinformation and disinformation are widespread and having adverse effects on individuals’ health decisions. How can we address the problem?
Latest:
HIV-Associated Neurocognitive Disorder: An Updated PathophysiologyIn this CME, learn more about the pathophysiology of HIV-associated neurocognitive disorder and to review the research and various tools used to aid in the diagnosis.
